UBS Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,567
| Closed | -$39.3K | – | 10325 |
|
|
2024
Q1 | $39.3K | Buy |
+4,567
| New | +$21.8K | ﹤0.01% | 6621 |
|
|
2023
Q2 | – | Sell |
-301
| Closed | -$11.4K | – | 9963 |
|
|
2023
Q1 | $11.4K | Buy |
301
+264
| +714% | +$8.65K | ﹤0.01% | 7509 |
|
|
2022
Q4 | $1.11K | Sell |
37
-7
| -16% | -$212 | ﹤0.01% | 9954 |
|
|
2022
Q3 | $1K | Buy |
+44
| New | +$1.68K | ﹤0.01% | 10112 |
|
|
2022
Q2 | – | Sell |
-241
| Closed | -$13K | – | 11188 |
|
|
2022
Q1 | $13K | Buy |
+241
| New | +$12.1K | ﹤0.01% | 8093 |
|
|
2021
Q4 | – | Sell |
-4
| Closed | – | – | 10887 |
|
|
2021
Q3 | $0 | Sell |
4
-106
| -96% | -$8.97K | ﹤0.01% | 10257 |
|
|
2021
Q2 | $14K | Sell |
110
-32
| -23% | -$4.43K | ﹤0.01% | 7728 |
|
|
2021
Q1 | $23K | Buy |
+142
| New | +$27.3K | ﹤0.01% | 7253 |
|
|
2020
Q4 | – | Sell |
-231
| Closed | -$23K | – | 8871 |
|
|
2020
Q3 | $23K | Sell |
231
-401
| -63% | -$21.5K | ﹤0.01% | 6217 |
|
|
2020
Q2 | $24K | Buy |
632
+569
| +903% | +$22.5K | ﹤0.01% | 6444 |
|
|
2020
Q1 | $2K | Sell |
63
-124
| -66% | -$7.2K | ﹤0.01% | 7663 |
|
|
2019
Q4 | $9K | Buy |
187
+153
| +450% | +$10.1K | ﹤0.01% | 7349 |
|
|
2019
Q3 | $3K | Sell |
34
-7
| -17% | -$718 | ﹤0.01% | 7672 |
|
|
2019
Q2 | $6K | Sell |
41
-4
| -9% | -$632 | ﹤0.01% | 7336 |
|
|
2019
Q1 | $12K | Hold |
45
| – | – | ﹤0.01% | 6704 |
|
|
2018
Q4 | $6K | Sell |
45
-29
| -39% | -$7.87K | ﹤0.01% | 7500 |
|
|
2018
Q3 | $31K | Buy |
74
+3
| +4% | +$1.39K | ﹤0.01% | 6518 |
|
|
2018
Q2 | $38K | Buy |
71
+45
| +173% | +$23.9K | ﹤0.01% | 6219 |
|
|
2018
Q1 | $12K | Sell |
26
-21
| -45% | -$11.5K | ﹤0.01% | 6771 |
|
|
2017
Q4 | $31K | Buy |
47
+10
| +27% | +$6.04K | ﹤0.01% | 6212 |
|
|
2017
Q3 | $23K | Sell |
37
-5
| -12% | -$2.6K | ﹤0.01% | 6357 |
|
|
2017
Q2 | $20K | Buy |
42
+19
| +83% | +$11.6K | ﹤0.01% | 6311 |
|
|
2017
Q1 | $17K | Hold |
23
| – | – | ﹤0.01% | 6275 |
|
|
2016
Q4 | $23K | Sell |
23
-2
| -8% | -$2.29K | ﹤0.01% | 6435 |
|
|
2016
Q3 | $33K | Buy |
25
+3
| +14% | +$3.38K | ﹤0.01% | 5851 |
|
|
2016
Q2 | $19K | Buy |
22
+7
| +47% | +$9.28K | ﹤0.01% | 6358 |
|
|
2016
Q1 | $21K | Hold |
15
| – | – | ﹤0.01% | 6170 |
|
|
2015
Q4 | $28K | Buy |
15
+12
| +400% | +$24K | ﹤0.01% | 6405 |
|
|
2015
Q3 | $5K | Sell |
3
-29
| -91% | -$67.8K | ﹤0.01% | 7737 |
|
|
2015
Q2 | $71K | Buy |
32
+19
| +146% | +$44.6K | ﹤0.01% | 5686 |
|
|
2015
Q1 | $36K | Buy |
+13
| New | +$34.2K | ﹤0.01% | 6356 |
|
Other funds holding TCON
UBS Group's TCON Position: Q2 2024 in Review
UBS Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 4,567 shares — an estimated $39.3K sold.
UBS Group first reported a position in TCON in Q1 2015 and held it in 31 quarters. The position peaked at $71K in Q2 2015. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- UBS Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 4,567 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $39.3K.
- UBS Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 31 quarters.
- UBS Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $71K in Q2 2015.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.